全球微量殘存疾病檢測市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2034 年，微量殘存疾病)檢測市場規模將從 2025 年的 33.4 億美元成長至 81 億美元，2026 年至 2034 年的複合年成長率為 10.33%。

由於癌症發生率上升以及對先進診斷技術的需求，全球微量殘存疾病（MRD）檢測市場正在成長。 MRD檢測有助於檢測治療後殘留的少量癌細胞，從而促進患者後續觀察並改善治療效果。醫療機構擴大採用這些檢測方法來評估治療效果並降低復發風險。分子診斷技術的進步是推動市場成長的重要因素。

推動市場成長的主要因素包括對個人化醫療日益成長的需求以及癌症治療策略的改進。次世代定序和流式細胞技術技術的進步提高了檢測的準確性和靈敏度。醫療保健支出的增加和人們對疾病早期檢測意識提升也促進了市場擴張。製藥公司正在臨床試驗中使用微小殘留病灶（MRD）檢測，這進一步加速了其在研究和醫療機構中的應用。

在精準醫療領域不斷創新的背景下，市場前景依然強勁。血液腫瘤和固態腫瘤研究的拓展將創造更多機會。在新興市場，醫療基礎設施的改善可望加速先進診斷工具的普及應用。在持續的技術進步和對早期檢測日益重視的推動下，全球微量殘存疾病）檢測市場預計將在未來幾年保持持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球微量殘存疾病）檢測市場：依技術分類

• 市場分析、洞察與預測
• 流式細胞技術（聚合酵素鏈鎖反應（PCR）、次世代定序（NGS））
• 其他

第5章：全球微量殘存疾病檢測市場：依癌症類型分類

• 市場分析、洞察與預測
• 骨髓惡性腫瘤
• 白血病
• 淋巴瘤
• 固態腫瘤

第6章：全球微量殘存疾病檢測市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院和專科診所
• 診斷檢查室
• 學術研究機構
• 其他

第7章 全球微量殘存疾病檢測市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Exact Sciences Corporation
  • GRAIL LLC
  • Veracyte Inc
  • Natera Inc
  • Guardant Health
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine Inc
  • Qiagen
  • Mdxhealth
  • Bio-Techne

The Minimal Residual Disease Testing Market size is expected to reach USD 8.10 Billion in 2034 from USD 3.34 Billion (2025) growing at a CAGR of 10.33% during 2026-2034.

The Global Minimal Residual Disease Testing Market is growing due to the rising incidence of cancer and the need for advanced diagnostic techniques. Minimal residual disease (MRD) testing helps detect small amounts of cancer cells that remain after treatment, improving patient monitoring and outcomes. Healthcare providers are increasingly adopting these tests to assess treatment effectiveness and reduce relapse risks. Technological advancements in molecular diagnostics are significantly contributing to market growth.

Key drivers include the growing demand for personalized medicine and improved cancer management strategies. Advances in next-generation sequencing and flow cytometry technologies have enhanced test accuracy and sensitivity. Increased healthcare spending and awareness about early disease detection are also supporting market expansion. Pharmaceutical companies are using MRD testing in clinical trials, further driving adoption across research and medical institutions.

Future prospects for the market remain strong as innovation continues in precision medicine. Expanding research in hematological cancers and solid tumors will create additional opportunities. Emerging economies are expected to adopt advanced diagnostic tools as healthcare infrastructure improves. With continuous technological progress and growing focus on early detection, the Global Minimal Residual Disease Testing Market is projected to witness sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Flow Cytometry (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS))
• Others

By Cancer Type

• Hematological Malignancy
• Leukemia
• Lymphoma
• Solid Tumors

By End Use

• Hospitals and Specialty Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Others

COMPANIES PROFILED

• Exact Sciences Corporation, GRAIL LLC, Veracyte Inc, Natera Inc, Guardant Health, F HoffmannLa Roche Ltd, Foundation Medicine Inc, Qiagen, mdxhealth, BioTechne
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Flow Cytometry (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Hematological Malignancy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Solid Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals and Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Cancer Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Cancer Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Cancer Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Cancer Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Cancer Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MINIMAL RESIDUAL DISEASE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Exact Sciences Corporation
  • 9.2.2 GRAIL LLC
  • 9.2.3 Veracyte Inc
  • 9.2.4 Natera Inc
  • 9.2.5 Guardant Health
  • 9.2.6 F. Hoffmann-La Roche Ltd
  • 9.2.7 Foundation Medicine Inc
  • 9.2.8 Qiagen
  • 9.2.9 Mdxhealth
  • 9.2.10 Bio-Techne